Truncated abstract] Significant morbidity and mortality is associated with cancer. Additionally, treatments for the disease are often highly toxic and associated with adverse side affects. Also, many cancers are resistant to currently available treatments. For these reasons, the search for new treatment options is ongoing. One area of research is immunotherapy; using the patients own immune system to clear the cancerous cells. Attempts to do this have had limited success, however, this is largely due to the lack of understanding of the interaction between tumour cells and the immune system. Supporting this, newer approaches like adoptive cell transfer have shown improved success. To continue making progress, continued research into the interaction between tumour cells and the immune system must be undertaken. One recent discovery is the involvement of regulatory T-cells (Tregs) in suppressing the host immune response towards the tumour cells. It is likely that any successful immunotherapy in the future will need to take into account the role that these cells play. With this in mind, before treatments can be developed that effectively target these cells in humans, a more thorough understanding of how these cells operate in cancer is required. This thesis aims to investigate the role of Tregs in the AE17 model of murine mesothelioma. Previous research in this laboratory have found that there is an accumulation of Tregs in the tumour. In addition, intra-tumoural injection with anti- CD25mAb to deplete the Treg results in inhibition of tumour growth for around 10 days. This thesis aims to expand upon these findings by investigating the changes in the immune system following anti-CD25mAb treatment in the AE17 model of murine mesothelioma. Chapter 3 investigated the depleting kinetics of the anti-CD25mAb treatment and the mechanisms associated with the anti-tumour effect observed.
|Qualification||Doctor of Philosophy|
|Publication status||Unpublished - 2010|